Abstract
Neoadjuvant concurrent chemoradiotherapy remains the standard treatment for locally advanced ESCC. Recent studies also revealed survival benefit from neoadjuvant chemotherapy alone while with limited pathological complete response (pCR) rate. This phase IB/II study aimed to evaluate the safety and efficacy of neoadjuvant Socazolimab, a novel PD-L1 inhibitor, combined with nab-paclitaxel/cisplatin for locally advanced ESCC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
